Consumer acceptability of a cancer registry-driven familial cancer testing pathway: a qualitative study using the Theoretical Framework of Acceptability [0.03%]
基于理论接受度框架的癌症登记驱动的家族性癌症检测路径消费者接受情况定性研究
Zoe Fehlberg,Sue M Evans,Maria Bechelli et al.
Zoe Fehlberg et al.
Background: Familial cancer test referral rates for rare tumors are suboptimal and follow a social gradient; while cancer registries are legally mandated to collect comprehensive clinical pathological data which could be ...
A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®) [0.03%]
关于身体处理低剂量尼洛替尼片剂（Danziti™）与现有胶囊（Tasigna®）的简化说明摘要
Michael Mauro,Jerald Radich,Dan Douer
Michael Mauro
Ilektra Kyrochristou,Georgios D Lianos,Gerasimia Kyrochristou et al.
Ilektra Kyrochristou et al.
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC) [0.03%]
TASUKI-52研究的通俗概述：评估纳武利尤单抗联合含铂化疗及贝伐珠单抗作为晚期或复发性非鳞状非小细胞肺癌（NSCLC）治疗的有效性和安全性的一项研究
Shunichi Sugawara,Jong-Seok Lee,Jin-Hyoung Kang et al.
Shunichi Sugawara et al.
The prognostic value of systemic immune-inflammation index and prognostic nutritional index for colorectal cancer cases with liver metastasis post-transcatheter arterial chemoembolization [0.03%]
肝动脉化疗栓塞后系统免疫炎症指数和预后营养指数对转移性结直肠癌的预后价值评估
Xingru Tan,Juncheng Wu,Zhengyu Jin
Xingru Tan
Aims: This study aimed to evaluate the prognostic value of the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) for overall survival (OS) in colorectal cancer (CRC) patients with liver metas...
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia [0.03%]
避免复发/难治性慢性淋巴细胞白血病进展和死亡的治疗人数及成本效益分析：泽布替尼对比阿卡替尼
Mazyar Shadman,Asher Chanan-Khan,David Campbell et al.
Mazyar Shadman et al.
Aims: In the absence of head-to-head comparative trials, this study aimed to compare zanubrutinib versus acalabrutinib in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) by calculating number needed to treat ...
Comparative Study
Future oncology (London, England). 2026 Feb;22(3):339-348. DOI:10.1080/14796694.2026.2615736 2026
Impact of immunotherapy on survival and treatment patterns of patients with extensive-stage small cell lung cancer: a study using a Japanese nationwide database [0.03%]
免疫治疗对广泛期小细胞肺癌患者生存和治疗模式的影响：基于日本全国数据库的一项研究
Yasutaka Ihara,Shoichiro Yamamoto,Megumi Mizutani et al.
Yasutaka Ihara et al.
Introduction: Although immune checkpoint inhibitor (ICI) therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) has shown promising results in clinical trials, it is not as widely used as for other can...
JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC [0.03%]
JADE III期研究：术前化疗放疗后序贯达洛西利玛b单药治疗局部晚期不可切除性HNSCC患者
Lillian L Siu,Barbara Burtness,Kevin Harrington et al.
Lillian L Siu et al.
Introduction: Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 5% of cancer cases worldwide, with more than half of patients presenting with locally advanced (LA) disease. Treatment of LA HNSCC is ...
Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors [0.03%]
酪氨酸激酶抑制剂治疗实体瘤儿童患者分子预选研究
Peter Sisovsky,Nikola Gejgusova,Tomas Fazekas et al.
Peter Sisovsky et al.
Aim: To review how molecular preselection and combination treatment affects overall response rate (ORR) in pediatric non-central nervous system (CNS) solid tumors treated with tyrosine kinase inhibitors (TKIs). ...
Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study [0.03%]
糖脂比在手术治疗子宫内膜癌患者预后价值的队列研究
Furkan Ceylan,Serhat Sekmek,Ateş Kutay Tenekeci et al.
Furkan Ceylan et al.
Background: The glucose-to-lymphocyte ratio (GLR) has recently gained attention as a composite biomarker reflecting systemic inflammation and metabolic dysregulation. While its prognostic value has been reported in variou...